Home › Research › Topics › pathology
pathology
12 studies tagged pathology, dated 1994-02-01 to 2026-01-05. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology 2026-01-05
- Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer's Disease pathology in Subjective Cognitive Decline and Mild Cognitive Impairment 2023-09-12
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology 2023-08-30
Studies
12 studies carry this tag.
Date range
1994 to 2026
Top journals
- Annals of clinical and translational neurology 2
- Journal of Alzheimer's disease : JAD 2
- Alzheimer's research & therapy 1
- Brain : a journal of neurology 1
- Cells 1
10 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Blood biomarkers have emerged as accurate tools for detecting Alzheimer's disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis.
-
Plasma p-tau181 levels were influenced by the presence of underlying AD pathology, independently from the cognitive status and were highly accurate in differentiating SCD-MCI patients who were carriers of AD pathology from non-carriers.
-
This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal.
-
Plasma p-tau181 is elevated in patients with ALS, independently from CSF levels, and is firmly associated with LMN dysfunction.
-
Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn (β = 0.31, 95% CI = 0.065-0.56, and P = 0.015), after covarying for age at plasma, plasma-to-death interval, and sex; plasma p-tau 181 was not (P = 0.37).
-
Alzheimer's disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ1-42), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer's disease pathology, and significantly improve diagnostic accuracy.
-
Improving LS7 scores might do a favor to alleviate the pathology of AD in the preclinical stage, especially among the APOE ε4 allele non-carriers.
-
50/100
This study is the first to find protective associations of serum ApoB with CSF AD core biomarkers, especially in SCD individuals.
-
Among mediators of inflammation, chemokines play a pivotal role in the neuroinflammatory process related to Alzheimer's disease (AD).
-
This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
-
Plasma proteins improved classification accuracy of AD pathology in cognitively-impaired older adults and appeared representative of amyloid pathology.
-
The protein products of the Jun and Fos immediate early gene (IEG) families are cooperative transcriptional regulatory factors implicated in regulating the expression of many genes.